170 related articles for article (PubMed ID: 28492978)
1. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.
Vecht C; Duran-Peña A; Houillier C; Durand T; Capelle L; Huberfeld G
J Neurooncol; 2017 Jul; 133(3):603-607. PubMed ID: 28492978
[TBL] [Abstract][Full Text] [Related]
2. WRAPPER study: Real-world effectiveness and tolerability of adjunctive perampanel for people with drug-resistant epilepsy in Hong Kong.
Chan CCH; Leung HW
Epilepsia Open; 2024 Feb; 9(1):345-354. PubMed ID: 38101856
[TBL] [Abstract][Full Text] [Related]
3. AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.
Lange F; Weßlau K; Porath K; Hörnschemeyer MF; Bergner C; Krause BJ; Mullins CS; Linnebacher M; Köhling R; Kirschstein T
PLoS One; 2019; 14(2):e0211644. PubMed ID: 30716120
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic brain activity differences in perampanel-responsive and non-responsive drug-resistant epilepsy patients: an EEG microstate analysis.
Zhu C; Li J; Wei D; Wu L; Zhang Y; Huang H; Lin W
Ther Adv Neurol Disord; 2024; 17():17562864241227293. PubMed ID: 38298737
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience with cenobamate: A systematic review and meta-analysis.
Makridis KL; Kaindl AM
Seizure; 2023 Nov; 112():1-10. PubMed ID: 37713961
[TBL] [Abstract][Full Text] [Related]
6. Drug resistant epilepsies: A multicentre case series of steroid therapy.
Falsaperla R; Collotta AD; Marino SD; Sortino V; Leonardi R; Privitera GF; Pulvirenti A; Suppiej A; Vecchi M; Verrotti A; Farello G; Spalice A; Elia M; Spitaleri O; Micale M; Mailo J; Ruggieri M
Seizure; 2024 Apr; 117():115-125. PubMed ID: 38394725
[TBL] [Abstract][Full Text] [Related]
7. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
Heuer S; Burghaus I; Gose M; Kessler T; Sahm F; Vollmuth P; Venkataramani V; Hoffmann D; Schlesner M; Ratliff M; Hopf C; Herrlinger U; Ricklefs F; Bendszus M; Krieg SM; Wick A; Wick W; Winkler F
BMC Cancer; 2024 Jan; 24(1):135. PubMed ID: 38279087
[TBL] [Abstract][Full Text] [Related]
8. Changes in Pre- and Postsurgery for Drug Resistant Epilepsy: Cognition and Sleep.
Li L; Lu J; Xu Y; Zhao Y
Biomed Res Int; 2022; 2022():9971780. PubMed ID: 35097128
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict the treatment benefit of perampanel in drug-resistant epilepsy patients.
Zhu C; Li J; Wei D; Wu L; Zhang Y; Huang H; Lin W
Front Neurol; 2023; 14():1284171. PubMed ID: 38093756
[TBL] [Abstract][Full Text] [Related]
10. Paws for Relief: Insights From the EPISODE Trial's Findings on the Role of Seizure Dogs in Treating Refractory Epilepsy.
Mbonde AA; Crepeau AZ
Neurology; 2024 Mar; 102(6):e209255. PubMed ID: 38417099
[No Abstract] [Full Text] [Related]
11. Tracing topics and trends in drug-resistant epilepsy research using a natural language processing-based topic modeling approach.
Karabacak M; Jagtiani P; Jain A; Panov F; Margetis K
Epilepsia; 2024 Apr; 65(4):861-872. PubMed ID: 38314969
[TBL] [Abstract][Full Text] [Related]
12. Pilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma.
Tobochnik S; Regan MS; Dorotan MKC; Reich D; Lapinskas E; Hossain MA; Stopka S; Santagata S; Murphy MM; Arnaout O; Bi WL; Antonio Chiocca E; Golby AJ; Mooney MA; Smith TR; Ligon KL; Wen PY; Agar NYR; Lee JW
medRxiv; 2024 Apr; ():. PubMed ID: 38645003
[TBL] [Abstract][Full Text] [Related]
13. The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions.
Tripathi S; Nathan CL; Tate MC; Horbinski CM; Templer JW; Rosenow JM; Sita TL; James CD; Deneen B; Miller SD; Heimberger AB
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38193532
[TBL] [Abstract][Full Text] [Related]
14. Perampanel Add-on to Standard Radiochemotherapy
Lange F; Hartung J; Liebelt C; Boisserée J; Resch T; Porath K; Hörnschemeyer MF; Reichart G; Sellmann T; Neubert V; Kriesen S; Hildebrandt G; Schültke E; Köhling R; Kirschstein T
Front Neurosci; 2020; 14():598266. PubMed ID: 33328869
[TBL] [Abstract][Full Text] [Related]
15. Management of Neurologic Complications in Patients with Brain and Spine Tumors.
V Bonm A; Taylor LP
Semin Neurol; 2024 Feb; 44(1):53-63. PubMed ID: 38176424
[TBL] [Abstract][Full Text] [Related]
16. Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel.
Izumoto S; Miyauchi M; Tasaki T; Okuda T; Nakagawa N; Nakano N; Kato A; Fujita M
Anticancer Res; 2018 Jul; 38(7):4361-4366. PubMed ID: 29970574
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.
Datta AN; Xu Q; Sachedina S; Boelman C; Huh L; Connolly MB
J Child Neurol; 2017 Aug; 32(9):834-839. PubMed ID: 28511603
[TBL] [Abstract][Full Text] [Related]
18. Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management.
Vecht C; Royer-Perron L; Houillier C; Huberfeld G
Curr Pharm Des; 2017; 23(42):6464-6487. PubMed ID: 29076421
[TBL] [Abstract][Full Text] [Related]
19. Behavioural changes in patients with intellectual disability treated with perampanel.
Andres E; Kerling F; Hamer H; Kasper B; Winterholler M
Acta Neurol Scand; 2017 Dec; 136(6):645-653. PubMed ID: 28568478
[TBL] [Abstract][Full Text] [Related]
20. The neuroprotective effect of perampanel in lithium-pilocarpine rat seizure model.
Wu T; Ido K; Osada Y; Kotani S; Tamaoka A; Hanada T
Epilepsy Res; 2017 Nov; 137():152-158. PubMed ID: 28624183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
